Avantor is continuing its investment to support the biopharma market with the opening of its new distribution center in Dublin, Ireland.
Avantor announced on Nov. 3, 2022 the opening of a new 69,000-ft2 distribution center in Dublin, Ireland. The facility is the most advanced distribution center in the company’s global network and enhances supply security due to its location to customers, according to a company press release.
The new facility will offer certified good manufacturing practice warehousing, on-site cleanrooms, batch-to-batch traceability, custom palletization, inbound and outbound product quality inspections, and vendor managed inventory solutions. The facility will also create 40 new jobs, adding to the 200 employees the company currently employs in Ireland.
"Avantor's value to the biopharma industry is our ability to support customers from discovery to delivery," said Ger Brophy, executive vice-president, Biopharma Production, in the release. "As a leading materials provider to the growing bioproduction industry, it is vital that we are responsive to customer needs in key markets such as Ireland while also having the capacity to meet growing demand in the region. This investment reflects our commitment to the industry and our anticipation of continued growth."
Source: Avantor
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.